<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; productivity</title>
	<atom:link href="http://www.tapanray.in/tag/productivity/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Criticality of Bridging the Skill Gap in Today’s Indian Pharma Industry</title>
		<link>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/#comments</comments>
		<pubDate>Sun, 17 Sep 2023 07:14:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PMKVY.40.]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[skilled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[workers]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10820</guid>
		<description><![CDATA[To address the shortage of adequately skilled workers in the country, in 2023, the Government of India released a new version of the national skill development initiative called Pradhan Mantri Kaushal Vikas Yojana 4.0 (PMKVY 4.0). It is touted as a &#8230; <a href="http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Creative Is Pharma Industry?</title>
		<link>http://www.tapanray.in/how-creative-is-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-creative-is-pharma-industry</link>
		<comments>http://www.tapanray.in/how-creative-is-pharma-industry/#comments</comments>
		<pubDate>Mon, 15 Apr 2019 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[creativity]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[gross]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mother]]></category>
		<category><![CDATA[necessity]]></category>
		<category><![CDATA[Operating]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[ROI]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9482</guid>
		<description><![CDATA[“Because the purpose of business is to create a customer, the business enterprise has two – and only two – basic functions: marketing and innovation. Marketing and innovation produce results; all the rest are costs. Marketing is the distinguishing, unique &#8230; <a href="http://www.tapanray.in/how-creative-is-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-creative-is-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interesting Link: Productivity At Work And Employee Fitness (Part 2)</title>
		<link>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-link-productivity-at-work-and-employee-fitness-part-2</link>
		<comments>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/#comments</comments>
		<pubDate>Mon, 23 Apr 2018 00:00:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Taboo]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8923</guid>
		<description><![CDATA[Part 2: Mental Fitness As I wrote in my previous article, the complex multi-factorial work-life challenges in today’s Volatile, Uncertain, Complex and Ambiguous (VUCA)) world are virtually unprecedented. Interestingly, a sizeable part of such challenge is related to a wide &#8230; <a href="http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-part-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An Interesting Link: Productivity At Work and Employee Fitness (In 2 Parts)</title>
		<link>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts</link>
		<comments>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/#comments</comments>
		<pubDate>Mon, 16 Apr 2018 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[exercises]]></category>
		<category><![CDATA[fitness]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mental]]></category>
		<category><![CDATA[NCD]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[VUCA]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8929</guid>
		<description><![CDATA[Part 1: Physical Fitness Today’s work environment is much more challenging than ever before. The challenge is undoubtedly multi-factorial. Many of these are external – mostly related to increasing complex, and difficult to fathom uncertainties and surprises in the overall &#8230; <a href="http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-link-productivity-at-work-and-employee-fitness-in-2-parts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Making New Cancer Drugs Cost-effective</title>
		<link>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=making-new-cancer-drugs-cost-effective</link>
		<comments>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/#comments</comments>
		<pubDate>Mon, 17 Apr 2017 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[cost-effective]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[repositioning]]></category>
		<category><![CDATA[repurposing]]></category>
		<category><![CDATA[Sildenefil]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thalidomide]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[viagra]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8188</guid>
		<description><![CDATA[The prices of new cancer drugs are increasingly becoming unsustainable across the world, and more so in India. A sizable number of poor and even middle-income patients, who spend their entire life’s savings for the treatment of this dreaded disease, &#8230; <a href="http://www.tapanray.in/making-new-cancer-drugs-cost-effective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/making-new-cancer-drugs-cost-effective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma R&amp;D: Chasing A Rainbow To Replicate The Past</title>
		<link>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-rd-chasing-a-rainbow-to-replicate-the-past</link>
		<comments>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/#comments</comments>
		<pubDate>Mon, 25 Jan 2016 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[exorbitant]]></category>
		<category><![CDATA[external]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Harmoni]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Nucala]]></category>
		<category><![CDATA[past]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replicate]]></category>
		<category><![CDATA[return]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Treshba]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7405</guid>
		<description><![CDATA[Would future be always a replica of the past? If the response is yes, the efforts of many global pharma players to replicate the successful Research and Development (R&#38;D) models of long gone by days, would continue to be a &#8230; <a href="http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-rd-chasing-a-rainbow-to-replicate-the-past/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘e-detailing’: The Future of Pharmaceutical Sales?</title>
		<link>http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=e-detailing-the-future-of-pharmaceutical-sales</link>
		<comments>http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/#comments</comments>
		<pubDate>Sun, 29 Sep 2013 23:30:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantages]]></category>
		<category><![CDATA[askpfizer]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[e-detailing]]></category>
		<category><![CDATA[effectiveness]]></category>
		<category><![CDATA[electronic]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[japanese]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pfizerline]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[traditional]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3751</guid>
		<description><![CDATA[Pharmaceutical product detailing to doctors by Medical Representatives (MRs) is believed to fetch the single largest return on marketing investments by the pharmaceutical companies globally, as on date. At the same time, the pharma players, across the world, are increasingly &#8230; <a href="http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/e-detailing-the-future-of-pharmaceutical-sales/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Balancing Strong IP Protection, Public Health Safeguards and Declining R&amp;D Productivity &#8211; A Crafty Gutsy Ball Game</title>
		<link>http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game</link>
		<comments>http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/#comments</comments>
		<pubDate>Mon, 16 Apr 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Balancing]]></category>
		<category><![CDATA[ball]]></category>
		<category><![CDATA[Crafty]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Gutsy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safeguards]]></category>
		<category><![CDATA[Strong]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=107</guid>
		<description><![CDATA[Pharmaceutical innovation has always been considered the lifeblood for the pharmaceutical industry and very rightly so. However, many studies do point out that such innovation has benefited the developed world more than the developing world. Product Price and Access: In &#8230; <a href="http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/balancing-strong-ip-protection-public-health-safeguards-and-declining-rd-productivity-a-crafty-gutsy-ball-game/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Seeing ghosts where there aren&#8217;t any</title>
		<link>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=seeing-ghosts-where-there-arent-any</link>
		<comments>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/#comments</comments>
		<pubDate>Mon, 10 Oct 2011 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[any]]></category>
		<category><![CDATA[aren't]]></category>
		<category><![CDATA[attractive]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[ghosts]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Seeing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[there]]></category>
		<category><![CDATA[viebachar]]></category>
		<category><![CDATA[where]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=190</guid>
		<description><![CDATA[Seeing ghosts almost everywhere in the Indian pharmaceutical industry, especially where there aren&#8217;t any, has indeed become quite common nowadays, across the spectrum of stakeholders. The ‘ghosts’ could well reside in ‘100% Foreign Direct Investments (FDI) through automatic route in &#8230; <a href="http://www.tapanray.in/seeing-ghosts-where-there-arent-any/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/seeing-ghosts-where-there-arent-any/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Frugal Innovation’ in Healthcare: Ahoy!</title>
		<link>http://www.tapanray.in/frugal-innovation-in-healthcare-ahoy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=frugal-innovation-in-healthcare-ahoy</link>
		<comments>http://www.tapanray.in/frugal-innovation-in-healthcare-ahoy/#comments</comments>
		<pubDate>Mon, 18 Apr 2011 00:30:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Ahoy]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[Frugal]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=273</guid>
		<description><![CDATA[Patented new products have been the prime growth driver of the research based pharmaceutical companies, the world over. Probably because of this reason the world has seen over a period of time about four different molecules of H2 Blockers and &#8230; <a href="http://www.tapanray.in/frugal-innovation-in-healthcare-ahoy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/frugal-innovation-in-healthcare-ahoy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
